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The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic
stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent
secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using
either myeloablative (n ¼ 242) or reduced-intensity conditioning (RIC; n ¼ 60) regimens reported to the
Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months
(range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% conﬁdence interval [CI],
38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival
was 22% (95% CI, 18%-27%). Multivariate analysis revealed a signiﬁcantly better overal survival with RIC
regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P <.001), with Karnofsky Performance Status score 90%
(HR, 0.62; 95% CI, 0.47-0.82: P ¼ .001) and in cytomegalovirus-negative recipients (HR, 0.64; 95% CI, 0.44-
0.94; P ¼ .022). A longer interval (>18 months) from auto-HCT to URD allo-HCT was associated withedgments on page 1107.
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J.M. Foran et al. / Biol Blood Marrow Transplant 19 (2013) 1102e1108 1103signiﬁcantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P <.001) and improved leukemia-free survival
(HR, 0.53; 95% CI, 0.34-0.84; P ¼ .006). URD allo-HCT after auto-HCT relapse resulted in 20% long-term
leukemia-free survival, with the best results seen in patients with a longer interval to secondary URD
transplantation, with a Karnofsky Performance Status score 90%, in complete remission, and using an RIC
regimen. Further efforts to reduce treatment-related mortaility and relapse are still needed.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION auto-HCT between 1995 and 2005. Patients undergoing allo-HCT using cord
Autologous hematopoietic bone marrow (BM) or
peripheral blood (PB) stem cell transplantation (auto-HCT)
can be an effective consolidation treatment associated with
improved leukemia-free survival (LFS) in adults with acute
myelogenous leukemia (AML) in randomized trials versus
intensive consolidation chemotherapy [1-3]. The beneﬁt of
auto-HCT appears to be especially apparent in patients with
favorable- and intermediate-risk AML [4,5] and in adults [6].
Posteauto-HCT treatment failure is related primarily to
relapse, particularly within the ﬁrst 2 years [7]. Relapse is
reportedly more likely in recipients of PB grafts [8] and in
patients who do not receive pretransplantation consolida-
tion chemotherapy [9]. Unfortunately, survival in patients
who relapse after auto-HCT is very poor [1,10]. Previous auto-
HCT is associated with both a lower likelihood of achieving
subsequent complete remission (CR) [10,11] and higher
mortality, and has been identiﬁed as an independent adverse
risk feature for survival in ﬁrst relapsed AML [10]. In view of
the poor outcomes with available therapies, patients who
relapse after auto-HCT are candidates for alternative strate-
gies or investigational therapy.
Some patients with relapsed AML undergo a secondary
allogeneic hematopoietic cell transplantation (allo-HCT)
after failure of auto-HCT, and long-term survival has been
noted, although often limited by high treatment-related
mortality (TRM) [12-19]. More recent reports have
described the use of RIC or nonmyeloablative conditioning
regimens (RIC/NMA) in an attempt to reduce TRM [20-26].
Patients in CR at the time of RIC/NMA appear to have
signiﬁcantly lower TRM and risk of relapse, as well as supe-
rior overall survival (OS). In limited series, similar OS was
reported with RIC or myeloablative (MA) conditioning in this
clinical setting [20,24].
Using the large multicenter observational database from
the Center for International Blood and Marrow Trans-
plantation Research (CIBMTR), we examined the outcomes of
secondary unrelated donor (URD) allo-HCT in patients with
AML who underwent previous unsuccessful auto-HCT, with
the aim of identifying patients and HCT techniques most
likely to be successful.
PATIENTS AND METHODS
Data Sources
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplantation Registry, Autologous Blood and Marrow Transplantation
Registry, and the National Marrow Donor Program. Established in 2004, the
registry receives data from more than 450 transplantation centers world-
wide on consecutive allo-HCTs and auto-HCTs with computerized checks for
discrepancies, physicians’ review of submitted data, and onsite audits of
participating centers ensure data quality. The CIBMTR collects detailed
clinical data pre-HCT, at 100 days and 6 months post-HCT, and annually
thereafter.
Observational studies conducted by the CIBMTR are performed with
approval of the Institutional Review Boards of the National Marrow Donor
Program and the Medical College of Wisconsin.
Patient Population
A total of 302 patients were reported to the CIBMTR who underwent
secondary URD allo-HCT for either relapsed or persistent AML after previousblood or related donors were excluded. Information on the previous auto-
HCT and lines of therapy after relapse for those achieving subsequent CR
was unavailable for the majority of the patients, and thus is not included in
this analysis.
Conditioning Regimens
Conditioning and graft-versus-host disease (GVHD) prophylaxis regi-
mens are shown in Table 1. CIBMTR deﬁnitions of MA and RIC/NMA condi-
tioning regimens (predominantly ﬂudarabine-based; see Table 1) and HLA
matching were applied [27,28]. For HLA matching, “well matched” was
deﬁned as no known disparity at HLA-A, -B, -C, or -DRB1; “partially
matched,” as a known or likely disparity at 1 locus; and “mismatched,” as
a disparity at 2 or more loci [29]. AML cytogenetics before auto-HCT were
categorized as “good,” “intermediate,” or “poor” risk according to the UK
Medical Research Council classiﬁcation scheme [30]. Patients with
t(7;12)(q36;p13), t(16;21)(q24;q22), or del(5q)/del(7q) were included in the
poor-risk group, and those with t(9;11) were included in the intermediate-
risk group [30-32].
Endpoints
The primary outcomes studied were TRM, relapse, LFS, and OS.
Secondary outcomes were hematopoietic recovery (neutrophil and platelet
engraftment) and the incidence of grade III/IV acute GVHD (aGVHD) and
chronic GVHD (cGVHD).
An event for LFS was death or hematologic relapse after allo-HCT, and an
event for OS was death from any cause. Surviving patients were censored at
the date of last contact. TRM was deﬁned as any death occurring before
leukemia relapse. Persistence of AML after allo-HCT was considered relapse
at day þ1 after allo-HCT.
Statistical Analysis
The analysis of outcomes after secondary URD allo-HCT considered
patient-related factors (age, sex, race, cytomegalovirus [CMV] serostatus,
Karnofsky performance status [(KPS] score, and serum bilirubin and creat-
inine levels) and disease-related factors (CR and cytogenetics), as well as
variables related to previous auto-HCT (time from auto-HCT to relapse and
to the secondary URD allo-HCT). Allo-HCTerelated variables considered
included donor age, race, sex, parity, and CMV status; PB versus BM graft and
cell dose (total nucleated cells for BM and total CD34þ cells for PB, if avail-
able); HLA matching and ABO compatibility; MA versus RIC/NMA condi-
tioning; GVHD prophylaxis (T cell depletion versus no T cell depletion); use
of growth factor post-HCT; and the incidence of aGVHD grade III/IV or
cGVHD of any severity as time-dependent variables.
Kaplan-Meier estimates were determined for OS and LFS, and the inci-
dence of TRM, relapse, and aGVHD and cGVHD were calculated using the
cumulative incidence function to accommodate competing risks. Analyses
were performed at a 5-year time point.
Multivariate analysis was conducted using the proportional hazards
model. All models were examined to conﬁrm compliance with the propor-
tional hazards assumption, and no violations of this assumption were
detected. A stepwise approach was then used to develop Cox regression
models for OS, LFS, and time to relapse and TRM for those in CR. Interactions
between signiﬁcant variables in the model were also considered for all
models.
RESULTS
Patient and Clinical Characteristics
A total of 302 patients who underwent secondary URD
allo-HCT between 1995 and 2005 for AML progression after
a previous auto-HCT were reported to the CIBMTR from 99
transplantation centers. Themedian patient agewas 38 years
(range, 1 to 65 years), 47% were male, and 90% were Cauca-
sian (Table 1). The median time from auto-HCT to URD allo-
HCT was 14 months (range 1 to 98 months), and this interval
was >6 months in 86% of the patients. The majority (72%) of
Table 2
Primary Outcomes
Outcome Event Number
Evaluable
Incidence
(95% CI), %
Neutrophil engraftment at
28 days
Platelet engraftment
(20,000  109/L) at 100 days
301 86 (83-90)
297 66 (61-71)
aGVHD grade III/IV at 100 days 302 25 (20-30)
cGVHD at 2 yrs 295 37 (31-42)
TRM 299
1 yr 44 (38-50)
5 yrs 48 (43-54)
Relapse 299
1 yr 25 (21-30)
5 yrs 32 (27-38)
LFS 299
1 yr 31 (26-36)
5 yrs 19 (15-24)
OS 302
1 yr 34 (29-40)
5 yrs 22 (18-17)
Figure 1. Cumulative incidence of relapse and TRM.
Table 1
Patient Characteristics
Characteristic Value
Number of patients 302
Number of centers 99
Age at transplantation, yrs, median (range) 38 (1-65)
Male sex, n (%) 141 (47)
KPS score 90%, n (%) 180 (60)
Race, n (%)
Caucasian 273 (90)
African-American 13 (4)
Hispanic 10 (3)
Asian 6 (2)
AML cytogenetic risk, n (%)
Good 26 (9)
Intermediate 184 (61)
Poor 13 (4)
Unknown 79 (26)
Conditioning regimen intensity, n (%)
MA 242 (80)
RIC/NMA 60 (20)
Conditioning regimen, n (%)
Cyclophosphamide þ total body irradiation 118 (39)
Busulfan þ cyclophosphamide 48 (16)
Total body irradiation þ/- other 41 (14)
Cyclophosphamide or busulfan þ/- other 35 (12)
Fludarabine þ/- melphalan þ/- other 56 (19)
Disease status before URD allo-HCT, n (%)
CR 223 (72)
Relapse 79 (26)
Time from autologous HCT to URD allo-HCT
Median (range), mo 14 (1-98)
6 mo, n (%) 42 (14)
>6 mo, n (%) 259 (86)
HLA match, n (%)
Well matched 105 (35)
Partially matched 148 (49)
Mismatched 49 (16)
Donor age, yrs, median (range) 36 (19-55)
Donor-recipient CMV serostatus, n (%)
þ/þ 75 (25)
þ/ 47 (16)
/þ 95 (31)
/ 79 (26)
Donor-recipient sex match, n (%)
Male-male 88 (29)
Male-female 52 (17)
Female-male 90 (30)
Female-female 66 (22)
Graft type, n (%)
BM 180 (60)
PB 122 (40)
Year of transplantation, n (%)
1995-1998 94 (32)
1999-2002 103 (34)
2003-2005 105 (35)
GVHD prophylaxis, n (%)
T cell depletion (in vivo or ex vivo) 40 (13)
Cyclosporine or tacrolimus þ
mycophenolate þ/ other
66 (22)
Cyclosporine or tacrolimus þ
methotrexate þ/ other
154 (52)
Cyclosporine or tacrolimus þ/ other 37 (12)
None 2 (<1)
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were in relapse. More than one-third (37%) of the patients
had a KPS score <90%. Among the 223 patients with cyto-
genetic information available, 80% were classiﬁed as inter-
mediate risk, and only 10% were classiﬁed as poor risk; 15
patients (5%) had acute promyelocytic leukemia.
The graft source was BM in 60% of the patients in PB in
40%. The majority of patients (80%) received MA condi-
tioning, and the remaining 20% received RIC/NMA condi-
tioning. There was a signiﬁcant trend toward increasing useof RIC during the study period; the use of RIC/NMA regimens
(versus MA) increased from 3 of 94 patients in 1995-1998 to
26 of 103 patients in 1999-2002 and to 31 of 105 patients in
2003-2005 (P <.001). Similarly, there was a signiﬁcant
increase in the use of RIC/NMA regimens (versus MA) with
increasing patient age, from 21 of 162 patients age<40 years
to 17 of 63 patients age 40-50 years and to 22 of 77 patients
age >50 years (P ¼ .005). The median duration of follow-up
in surviving patients was 58 months (range, 2 to
160 months).
Hematopoietic Recovery and GVHD
Neutrophil and platelet recovery, along with the inci-
dences of grade III/IV aGVHD at 100 days and of cGVHD at
2 years, are reported in Table 2. In multivariate analysis, the
only factors signiﬁcantly associated with the development of
GVHD were CMV status (aGVHD) and use of a PB graft
(cGVHD). There was a signiﬁcantly lower incidence of grade
III/IV aGVHD in CMV-negative donorerecipient pairs (HR,
0.37; 95% CI, 0.18-0.78; P ¼ .009), whereas recipients of PB
grafts (versus BM) were 70% more likely to develop cGVHD.
Outcomes
The probabilities of relapse, TRM, and OS at 1 year and at
5 years are presented in Table 2 and shown in Figures 1 and 2.
Relapse
The greatest risk of relapse after URD allo-HCT was during
the ﬁrst year posttransplantation, with very few relapses
Figure 2. Probabilities of OS and LFS.
Table 3
Multivariate Analysis for Primary Outcomes
n HR 95% CI P Value
OS
KPS score
<90% 109 1.00*
90% 167 0.62 0.47-0.82 .001
Conditioning regimen
MA 217 1.00*
RIC/NMA 59 0.51 0.35-0.75 <.001
Graft source and disease status
at allo-HCT
.013
BM
CR 124 1.00*
Relapse 43 1.17 0.79-1.74 .431
PB
CR 77 1.00*
Relapse 32 3.26 2.01-5.27 <.001
Donor/recipient CMV serostatus
þ/þ 76 1.00*
þ/ 38 0.49 0.30-0.79 .004
/þ 89 1.13 0.80-1.59 .48
/ 73 0.64 0.44-0.94 .022
Grade III/IV aGVHDy
No 199 1.00*
Yes 77 1.92 1.36-2.71 <.001
cGVHDy
No 168 1.00*
Yes 108 1.20 0.81-1.79 .356
Relapse
KPS score
<90% 108 1.00*
90% 171 0.45 0.29-0.71 <.001
Time from auto-HCT to URD
allo-HCT
<6 mo 40 1.00*
6-12 mo 87 0.48 0.26-0.88 .018
12-18 mo 61 0.32 0.16-0.64 .001
>18 mo 91 0.19 0.09-0.38 <.001
Grade III/IV aGVHDy
No 201 1.00*
Yes 78 1.57 0.92-2.65 .095
cGVHDy
No 170 1.00*
Yes 109 0.94 0.54-1.64 .821
TRM
Conditioning regimen
MA 221 1.00*
RIC/NMA 58 0.52 0.31-0.88 .015
HLA match
Well matched 95 1.00*
Partially matched 138 1.39 0.91-2.14 .128
Mismatched 46 1.93 1.15-3.24 .012
Graft source and disease status
at allo-HCT
BM
CR 126 1.00*
Relapse 43 1.08 0.68-1.72 .751
PB
CR 78 1.00*
Relapse 32 3.05 1.6-5.83 <.001
Grade III/IV aGVHDy
No 201 1.00
Yes 78 2.34 1.51-3.64 <.001
cGVHDy
No 170 1.00*
Yes 109 1.82 1.06-3.12 .031
LFS
KPS score
<90% 108 1.00*
90% 171 0.63 0.48-0.84 .001
Donor/recipient CMV serostatus
þ/þ 76 1.00*
þ/ 39 0.48 0.30-0.76 .002
/þ 90 1.00 0.72-1.41 .979
/ 74 0.60 0.42-0.88 .008
(continued on next page)
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analysis, the interval from auto-HCT to URD allo-HCT
signiﬁcantly inﬂuenced the subsequent risk of relapse, with
a progressively lower risk of relapse seen with longer
posteauto-HCT intervals (>18 months) compared with short
intervals (<6 months) (Table 3). Patients with a KPS score
90% were signiﬁcantly less likely to relapse, whereas the
development of cGVHD was not independently associated
with relapse.
TRM and Causes of Death
Among the 231 deaths, the major causes were relapsed
AML (26%), infection (20%), organ failure (14%), interstitial
pneumonitis (13%), GVHD (11%), and other causes (16%). TRM
was the leading cause of treatment failure after salvage URD
allo-HCT, and the risk of TRM was greatest in the ﬁrst year
(Table 2 and Figure 1). In multivariate analysis, HLA-
mismatched URD was associated with signiﬁcantly worse
TRM (hazard ratio [HR], 1.93; 95% conﬁdence interval [CI],
1.15-3.24; P¼ .012), but did not impact OS, whereas the use of
RIC/NMAwas protective for TRM (HR, 0.52; 95% CI, 0.31-0.88;
P ¼ .015) (Table 3). Patients receiving RIC/NMA had a 20%
lower absolute TRM at 1 year (Table 4), which was associated
with improved OS (see below).
There was a signiﬁcant interaction in the analysis
between graft type (PB versus BM) and disease status (CR
versus not in CR at allo-HCT). In patients undergoing trans-
plantation with PB (but not BM) grafts, those not in CR had
3-fold higher risk of TRM (P <.001).
LFS and OS
For the entire cohort, 5-year LFS was 19% (95% CI, 15%-
24%) (Table 2 and Figure 2). A longer interval (>18 months)
from auto-HCT to secondary URD allo-HCT was associated
with signiﬁcantly better LFS, as was the use of RIC/NMA
conditioning (Table 3). In contrast, those who received a PB
(but not BM) graft and who were not in CR at allo-HCT had
a more than 2-fold greater risk for death or relapse (HR, 2.30;
95% CI 1.39-3.79; P¼ .001). In our model, the development of
grade III/IV aGVHD was associated with signiﬁcantly worse
LFS and OS, whereas cGVHD was not independently associ-
ated with LFS or OS.
In the multivariate analysis of OS, the risk for death was
signiﬁcantly lower in patients receiving an RIC/NMA (versus
MA) conditioning regimen (HR, 0.51; 95% CI, 0.35-0.75;
P <.001), in patients with a KPS score 90% at the time of
URD allo-HCT (HR, 0.62; 95% CI, 0.47-0.82; P ¼ .001), and
among CMV-negative donorerecipient pairs (HR, 0.64; 95%
Table 3
(continued)
n HR 95% CI P Value
Time from auto-HCT to URD
allo-HCT
<6 mo 40 1.00*
6-12 mo 87 0.72 0.47-1.10 .127
12-18 mo 61 0.61 0.38-0.99 .045
>18 mo 91 0.53 0.34-0.84 .006
Conditioning regimen
MA 221 1.00*
RIC/NMA 58 0.55 0.37-0.8 .002
Graft source and disease status
BM
CR 126 1.00*
Relapse 43 1.06 0.71-1.58 .759
PB
CR 78 1.00*
Relapse 32 2.30 1.39-3.79 .001
Grade III/IV aGVHDy
No 201 1.00*
Yes 78 1.84 1.31-2.59 <.001
cGVHDy
No 170 1.00*
Yes 109 1.30 0.87-1.94 .193
* Reference group.
y aGVHD and cGVHD included as time-dependent covariates.
Table 5
OS Based on Time from Autologous HCT to Secondary URD Allo-HCT
Interval n OS (95% CI)
at 1 yr, %
OS (95% CI)
at 5 yrs, %
6 mo 42 14 (5-27) 11 (3-24)
6-12 mo 91 32 (23-42) 22 (14-31)
12-18 mo 71 36 (25-47) 20 (11-31)
>18 mo 97 42 (32-52) 30 (21-40)
P value .003 .089
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improvement in OS was seen in patients receiving an RIC/
NMA regimen (versus an MA conditioning regimen), owing
predominantly to lower TRM (Table 4).
A longer time interval between auto-HCT to secondary
URD allo-HCT was also associated with signiﬁcantly better
1-year OS and with a trend toward signiﬁcantly better 5-year
OS. Patients with a >18-month interval had a 42% 1 year OS,
compared with the 14% in those with a very short
(<6 months) interval (P ¼ .003) (Table 5).
Multivariate Analysis to Identify a Favorable Subgroup
To identify those patients most likely to beneﬁt from our
proposed approach, we examined OS using those clinical risk
factors identiﬁed in the multivariate model that would be
apparent before URD allo-HCT (ie, not in CR, KPS score <90%,
MA conditioning, and CMV-positive status). We also
included a <18-month interval from auto-HCT in the model,
given that this was signiﬁcant for OS, had a signiﬁcant impact
on LFS and relapse, and is a clinically relevant factor in
patient selection for salvage URD allo-HCT.
Survival, categorized by the presence of these 5 risk
factors, is shown in Figure 3 (P <.001). The 35 patients (12%)
with 0 or 1 risk factors had a 5-year OS of approximately 50%.
In contrast, thosewith 4 or 5 risk factors (n¼ 90,w30% of the
cohort) had a 5-year OS of <10%, and there were no 5-year
survivors with all 5 adverse risk factors. Patients with 2 or
3 risk factors had an intermediate projected 5-year OS of
20%-25% (Figure 3).
DISCUSSION
In this large comprehensive study of secondary URD allo-
HCT for AML after failed auto-HCT, approximately 20% of theTable 4
Clinical Outcome Based on Intensity of Allo-HCT Conditioning Regimen
Outcome MA
(n ¼ 242)
RIC/NMA
(n ¼ 60)
P Value
TRM (95% CI) at 1 yr, % 48 (41-54) 28 (17-41) .004
OS (95% CI) at 1 yr, % 30 (25-36) 50 (37-63) .007
OS (95% CI) at 5 yrs, % 19 (14-24) 37 (25-51) .009patients achieved long-term survival. This percentage
compares favorably with historical experience, for example,
with the 4% 5-year survival reported by the Dutch-Belgian
and Swiss Collaborative Groups in a cohort of 102 patients
with failed auto-HCT [10]. Patients with later relapse after
auto-HCT (beyond 18 months), those in CR, those with a KPS
score 90%, and those receiving an RIC/NMA regimen
demonstrate the best outcomes after URD allo-HCT in this
setting. Indeed, one-half of our patients in CR, with a KPS
score90%, and a long interval (>18months) from auto-HCT
achieved long-term survival with the use of an RIC/NMA
regimen, demonstrating that appropriate patient selection is
necessary to capitalize on the beneﬁts of this approach.
Even though our patients represent a selected cohort, the
ﬁnding of 22% OS at 5 years in this very high-risk population
may reﬂect an active graft-versus-leukemia effect. The inci-
dence of cGVHD in our series was somewhat lower than
expected, with other recent large reports of URD allo-HCT in
acute leukemia suggest an incidence closer to 50% [33].
While this might be a function of the high TRM and the
inclusion of patients not in CR at the time of secondary URD
allo-HCT, nevertheless cGVHD was not independently asso-
ciated with any improvement in leukemia control in our
analysis.
The practice of consolidation with allo-HCT in relapsed
AML is well established, and earlier reports suggested that
secondary allo-HCT might be an effective therapy in some
patients with relapsed AML after auto-HCT. In a European
Group for Blood and Marrow Transplantation study, Ringden
et al. [18] reported a 37% 2-year OS in a group of 62 patients
with acute leukemia who underwent allo-HCT from HLA-
matched related (n ¼ 29) and unrelated (n ¼ 33) donors.
Blau et al. [16] described 5 of 10 patients who become long-
term survivors (248-1140 days) after posteauto-HCT URD
allo-HCT. In another study, Radich et al. [17] evaluatedFigure 3. Probability of OS according to 5 risk factors at the time of secondary
URD allo-HCT: <18-month interval from auto-HCT to secondary URD allo-HCT,
not in CR, KPS score <90%, MA conditioning, and positive CMV serostatus. P
<.001.
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who relapsed after initial auto-HCT, 20 of whom underwent
secondary matched URD allo-HCT, with a 2-year disease-free
survival (DFS) of 19%. Univariate analysis of all 59 patients
showed that superior DFS was associated with age<17 years,
remission at the time of allo-HCT, use of total body
irradiationebased conditioning regimen for allo-HCT, and
a diagnosis of AML. The type of donor (related versus unre-
lated) did not appear to inﬂuence DFS.
The duration of CR is an established prognostic factor in
relapsed AML, and achievement of subsequent CR was an
important prognostic factor for survival after secondary URD
allo-HCT in our analysis. Unfortunately, detailed information
on remission status at the time of the original auto-HCT was
available for fewer than one-half of our patients (although
>90% of thosewere in ﬁrst CR). Moreover, information on the
duration of CR after auto-HCT was not available, and thus
neither variable could be formally included in our analysis.
Nevertheless, the signiﬁcant association between the
interval to secondary URD allo-HCT and subsequent clinical
outcomes (especially after 6 months) suggests that the
duration of CR after initial auto-HCT is an important prog-
nostic factor in this setting.
The present CIBMTR study highlights the importance of
patient selection for URD allo-HCT. Patients with a brief
interval from auto-HCT to salvage URD allo-HCT, those not in
CR before HCT, and particularly those with compromised
performance status have signiﬁcantly worse outcomes.
Based on our analysis, patients with more than 3 identiﬁed
risk factors generally are not recommended for HCT as
a routine practice. In contrast, those with late relapse, with
a good KPS score, and in CR at second URD allo-HCTappear to
beneﬁt the most from this approach.
Although our results describe the actual survival of our
consecutive cohort of patients, there is always potential bias
in identifying risk factors for clinical outcomes in a retro-
spective analysis. We have attempted to minimize this bias
by broadly incorporating all known and available clinical or
transplantation-related data that might inﬂuence outcome
and using appropriate statistical methods. The risk factors
identiﬁed for clinical outcome have potential clinical appli-
cation, applying to both patient and donor selection (eg, KPS
score, CMV status) as well as to disease status (eg, CR,
interval from auto-HCT) and the URD allo-HCT treatment
itself (eg, choice of conditioning regimen). Thus, this analysis
may allow for more reﬁned patient and donor selection and
may help guide future practice in this setting.
TRM was the leading cause of treatment failure in our
cohort. Although only 20% of the patients received an RIC/
NMA regimen, this conditioning regimen was associated
with signiﬁcantly lower TRM and better survival compared
with MA regimens. Unsurprisingly, the use of RIC/NMA
regimens increased over time and with patient age. This
result likely reﬂects HCT in a more recent era [34], and
suggests that conditioning regimens that reduce TRM will
yield better outcomes in the setting of secondary URD allo-
HCT [26]. The adverse impact of aGVHD on survival is also
not surprising [20], and further efforts are needed to
diminish the impact of aGVHD on TRM and OS, possibly
through strategies that directly target the greater GVHD risks
with increasing HLA disparities.
An interaction between disease status (CR versus relapse)
and graft source (PB versus BM) was observed, with a 2-fold
increased risk for death and treatment failure for those who
received a PB graft and were not in CR at the time ofsecondary URD allo-HCT. The reasons for this interaction are
not known, but might reﬂect selection of a PB graft for
higher-risk patients in this setting.
Cytogenetic risk was not an independent risk factor for
outcome, likely because the large majority of patients in this
analysis were at intermediate risk or had unknown cytoge-
netics. This is a potential limitation of this study, given that
only 4% of those who received salvage URD allo-HCT had
known poor-risk cytogenetics. This may reﬂect either an
inability to achieve adequate disease control to allow HCT in
patientswith higher-risk AMLor the selection of patientswith
intermediate-risk cytogenetics for initial auto-HCT who may
be the most likely to beneﬁt from that treatment. Neverthe-
less, our results with secondary URD allo-HCT may be most
applicable to patients with intermediate-risk cytogenetics.
In conclusion, our ﬁndings demonstrate that appropri-
ately selected patients may achieve long-term survival from
secondary URD allo-HCT after failure of previous auto-HCT.
Further studies to improve outcomes must focus on
improved pretransplantation salvage regimens and alterna-
tive RIC regimens with better antileukemia efﬁcacy, along
with possible posttransplantation monitoring and mainte-
nance strategies to enhance disease control and limit
peritransplantation mortality.
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